LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
http://www.lilly.com

SectorHealthcare
IndustryDrug Manufacturers—General
Full Time Employees33,625

Key Executives

NameTitlePayExercisedYear Born
Mr. David A. RicksChairman, CEO & Pres4.4MN/A1968
Mr. Joshua L. SmileySr. VP & CFO2.13MN/A1970
Dr. Daniel M. SkovronskySr. VP, Chief Scientific Officer & Pres of Lilly Research Labs2.14MN/A1975
Mr. Jacob S. Van NaardenChief Operating Officer of Loxo OncologyN/AN/A1985
Mr. Donald A. ZakrowskiChief Accounting Officer & VP of Fin.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; and Avidity Biosciences, Inc., as well as AbCellera Biologics Inc. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Corporate Governance

Eli Lilly and Company’s ISS Governance QualityScore as of December 3, 2019 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.